Hovione Appoints Kristine Senft Vice President, Sales And Marketing

LOURES, Portugal, October 12, 2015 /PRNewswire/ --

Hovione announced today the appointment of Ms. Kristine Senft as Vice President Sales and Marketing. Ms. Senft joined Hovione on the 1st October and will succeed Mr. Dave Hoffman Vice President Sales and Business Development when he retires in April 2016. Ms. Senft was most recently with DSM and brings a vast experience in Sales and Marketing. Based in East Windsor, New Jersey, Ms. Senft will report to Guy Villax, Hovione's Chief Executive Officer.

"Hovione is delighted to welcome Ms. Senft to our management team. I very much look forward to working with Kristine. Kristine brings to Hovione exactly what we need as we enter this next phase of growth," said Guy Villax.

"I am delighted to join Hovione, a company with a dynamic team and a strong history that understands the nature of leading through innovation. I look forward to building on what has been achieved by Hovione to date in its creation of solutions for customers," said Ms. Senft.

Before joining Hovione, Ms. Senft previously served various roles as a Business Unit Director, DSM Biomedical and before that as SVP, Marketing and Sales, DSM Pharmaceutical Chemicals where she led both regional and global marketing and sales organizations while experiencing expatriate life in Vienna, Austria, working with many of the top global pharma and biopharma companies. She also worked for Albemarle Corporation for many years in mainly Sales and Business Management roles in their Fine Chemicals and Pharmaceutical API businesses.

Ms. Senft was also Co-Chair of the Women's Initiative Network at Albemarle and was an executive member of the DSM Diversity Council. During her career she served on the Society of Chemical Manufacturers Association (SOCMA) Communications Committee and Membership Committee for several years. She is an active supporter of the Drug, Chemical and Associated Technologies Association (DCAT), DCAT Week and has recently served on the DCAT Board of Directors. While residing in Europe she was also associated with the European Fine Chemicals Group (EFCG).

Ms. Senft graduated from Eastern Illinois University with a BSc in Chemistry. She recently (2014) completed the Executive Leadership Program with DSM / Wharton, University of Pennsylvania.

About Hovione

Hovione is an international company with over 50 years' experience in the development and compliant manufacture of Active Pharmaceutical Ingredients and Drug Product Intermediates. With four FDA inspected sites in the U.S., China, Ireland, and Portugal, the company focuses on the most demanding customers, in the most regulated markets. The company also offers branded pharmaceutical customers services for the development and compliant manufacture of innovative new drugs, is able to support highly potent compounds and offers proprietary product development and licensing opportunities for drug products. In the inhalation area, Hovione is the only independent company offering such a broad range of services. Hovione is a member of Rx-360, EFCG and APIC and is active in the standard setting process of our industry, this reflects its commitment to higher global industry standards. http://www.hovione.com

Contact
Isabel Pina
Director of Corporate Communications
Tel.: +351-21-982-9362
[email protected]

SOURCE Hovione
 

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

While the biotech IPO market booms, it can look like going public is easy. But the right strategy, syndicate and aftermarket are still important.

Gene therapy pioneer Jim Wilson and the University of Pennsylvania are teaming up with Regeneron to help deliver its COVID antibody intransally.

Forty percent of PK deficiency patients on mitapivat had hemoglobalin responses, compared to 0% in the placebo group.